【摘要】 近年来，我国前列腺癌发病率与死亡率持续上升，疾病负担日益加重。随着精准医学理念的普及及相关药物研发的不断进展，前列腺癌在疾病全程管理的各个阶段均取得了显著成效。本文聚焦于局限性前列腺癌的精准诊疗革新、转移性激素敏感性前列腺癌（metastatic hormone-sensitive prostate cancer,mHSPC）的强化治疗前移与精准分层，以及转移性去势抵抗性前列腺癌（metastatic castration-resistant prostate cancer,mCRPC）的新机制突破这3大主题，系统梳理与总结了2025年度重要的临床研究进展。更多还原

【Abstract】 In recent years, the incidence and mortality rates of prostate cancer in China have continued to rise, leading to an increased disease burden. The widespread adoption of precision medicine principles, coupled with advancement of drug research, has significantly transformed the management of prostate cancer at each stage. This article systematically reviews and summarizes the key clinical research progress in 2025 around three major themes: the innovation of precision diagnosis and treatment for localized prostate cancer, the forward-moving of intensified treatment and precision stratification for metastatic hormone-sensitive prostate cancer(mHSPC), and the breakthrough of new mechanism for metastatic castration-resistant prostate cancer(mCRPC).更多还原